Accessibility Menu
Crescent Biopharma logo

Crescent Biopharma(NASDAQ) CBIO

Market Cap$534.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-5%
5 Year-93%
1 Year+17%
1 Month-15%
$14.45
-3.80%
-0.57Today
After hours$14.47+$0.02 (+0.14%)
Crescent Biopharma last closing stock price
MetricPriceDate
Last closeUSD 14.472026-07-31
Crescent Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.23%USD 16.302026-07-24
1 month-15.28%USD 17.082026-07-01
3 month-19.92%USD 18.072026-05-01
Year to date+22.01%USD 11.862025-12-31
1 year+16.51%USD 12.422025-07-31
3 year-91.23%USD 165.002023-08-01
5 year-92.84%USD 202.002021-07-30
Since inception-4.91%USD 15.802025-06-16

Crescent Biopharma Financials at a Glance

Market Cap

$534.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.88M

Net Income (TTM)

-$140.29M

EPS (TTM)

-$7.65

P/E Ratio

-1.89

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$14.45

Volume

292,515.885

Open

$15.14

Previous Close

$14.47

Daily Range

$13.99 - $15.14

52-Week Range

$8.72 - $27.41

Estimated Earnings Date

Nov 5, 2026

CBIO News

No articles available.

CBIO: Motley Fool Moneyball Superscore

47

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Crescent Biopharma

Crescent Biopharma develops new medicines for people with cancer. Its main focus is on therapies for solid tumors, which are common in many cancers.

What’s in the Crescent Toolbox?

CR-001 (Bispecific Antibody): Combines two targets to help the immune system fight solid tumors; 0% of revenue as of June 2025.

CR-002 (Antibody-Drug Conjugate): Links an antibody to a cancer-killing drug for targeted therapy; 0% of revenue as of June 2025.

CR-003 (Antibody-Drug Conjugate): Targets three different cancer markers; in early research; 0% of revenue for Q2 2025.

Research Partnerships: Collaborates with Paragon Therapeutics for drug discovery and WuXi Biologics for manufacturing; no direct revenue.

Single-Segment Focus: All activities center on oncology drug development; no commercial sales yet.

Growth Moves: Crescent’s Playbook

Completed a reverse recapitalization with GlycoMimetics in 2025, gaining a new capital structure and public listing.

Secured exclusive global rights for CR-001 from Paragon Therapeutics in April 2025.

Expanded research agreement with Paragon Therapeutics in April 2025 to add CR-003.

Raised $200.0 million in pre-closing financing just before the June 2025 recapitalization.

Opened a new office in Waltham, Massachusetts in June 2025.

Why Crescent Isn’t Just Another Biotech

Crescent relies on external partners for research and manufacturing, keeping its team lean. The company focuses on advanced antibody technologies to address gaps in cancer treatment. Its business model centers on partnerships and licensing, not in-house manufacturing or sales.

Five Things You Need to Know

No revenue reported for Q2 2025 or prior periods; all products are pre-commercial.

Net loss was $21.8 million in Q2 2025, up 103% from Q2 2024.

Cash flow was $5.08 billion in Q2 2025, up 57,207% from Q2 2024.

Cash position was $152.6 million as of Q2 2025.

All research and development spending targets oncology, with $22.7 million spent in the first half of 2025.

Bottom Line

Crescent is an early-stage biotech focused on cancer therapies, with no product sales yet. Its growth depends on partnerships, external funding, and advancing its drug pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

44

CEO

Joshua T. Brumm

Website

www.crescentbiopharma.com

Headquarters

Waltham, MA 02451, US

CBIO Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1417.74%

Net Income Margin

-1180.57%

Return on Equity

-84.16%

Return on Capital

-74.58%

Return on Assets

-76.76%

Earnings Yield

-52.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$534.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

36.96M

Volume

292.52K

Avg. Volume

363.28K

Financials (TTM)

Gross Profit

$11.88M

Operating Income

-$168.47M

EBITDA

-$164.51M

Operating Cash Flow

-$72.68M

Capital Expenditure

-$72.94M

Free Cash Flow

-$145.62M

Cash & ST Invst.

$171.59M

Total Debt

$1.44M

Crescent Biopharma Performance Analysis

Crescent Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 75,000-93.5%
20232023-12-31USD 10,000-86.7%
20242024-12-31USD 0N/A
20252025-12-31USD 10,844,000N/A
Crescent Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-90.4%
Q22026-06-30-100.0%
Crescent Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -88.88-27.9%
20232023-12-31USD -58.25-34.5%
20242024-12-31USD -23.28-60.0%
20252025-12-31USD -14.78-36.5%
Crescent Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3074.2%
Q42025-12-31-215.7%
Q12026-03-3182.5%
Q22026-06-30-106078.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$534.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.15M

N/A

Employees

44

N/A

Net Income

$0.00

+100.0%

EBITDA

-$26.36M

-27.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$171.59M

+12.4%

Total Debt

$1.44M

-12.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$966.00K

-32.6%

Short Term Debt

$471.00K

+123.2%

Return on Assets

-76.76%

N/A

Return on Invested Capital

-1.03%

N/A

Free Cash Flow

-$19.48M

-17.7%

Operating Cash Flow

-$19.46M

-18.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CCCCC4 Therapeutics, Inc.
$3.48-4.92%
OABIOmniAb, Inc.
$1.98-0.50%
CGENCompugen Ltd.
$2.35+0.64%
IPHAInnate Pharma S.A.
$1.75+0.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About CBIO

What is the current price of Crescent Biopharma?

Crescent Biopharma is trading at $14.47 per share.

What is the 52-week range for Crescent Biopharma?

Over the past 52 weeks, Crescent Biopharma has traded between $8.72 and $27.41.

How much debt does Crescent Biopharma have?

As of the most recent reporting period, Crescent Biopharma reported total debt of $1.44M.

How much cash does Crescent Biopharma have on hand?

Crescent Biopharma reported $171.59M in cash and cash equivalents in its most recent financial results.

What is Crescent Biopharma’s dividend yield?

Crescent Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services